A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

Inclusion Criteria: * Type 1 Diabetes Mellitus (as diagnosed clinically) ≥ 12 months * Treated with multiple daily injection ≥ 12 months * Treated with insulin glargine U100 or U300 or insulin detemir at screening * Fasting C-peptide ≤ 0.30 nmol/L * BMI: 18.5-28.0 kg/m² (both inclusive) Exclusion Criteria: * Known or suspected hypersensitivity to IMPs, paracetamol or related products * Type 2 Diabetes Mellitus * Clinically significant abnormal haematology, biochemistry or urinalysis screening test, as judged by the investigator considering the underlying disease * Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea), as judged by the investigator * Known slowing of gastric emptying, including gastroparesis and or gastrointestinal surgery that in the opinion of the investigator, might change gastrointestinal motility and food absorption * Intake of medication known to affect gastrointestinal motility, including but not limited to erythromycin, metoclopramide, cisapride, cholestyramine or colestipol within 4 weeks before screening